Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC_EX:A61K39/42

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/102904PCDH1-BINDING AGENTS AND USES THEREOF
WO 28.05.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CA2019/051669 Applicant THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO Inventor MOFFAT, Jason
The disclosure is directed to novel PCDH-1-binding agents, and to methods and uses of these binding agents. In one embodiment, the disclosure provides antibody variable regions which specifically bind the EC1 domain of PDCH1. The disclosure is also directed to uses of the novel PCDH1-binding agents for treating or preventing infection with New-World hantavirus.
2.WO/2020/106713ANTIBODY THERAPIES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV)
WO 28.05.2020
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2019/062203 Applicant BETH ISRAEL DEACONESS MEDICAL CENTER, INC. Inventor BAROUCH, Dan, H.
Featured are PGDM1400 variant antibodies or fragments thereof, which can be administered, e.g., as antibody therapies for treating human immunodeficiency virus (HIV) infection. In particular, featured are methods of treating or curing subjects infected with HIV and/or preventing HIV infections in subjects at risk of HIV transmission using the PGDM1400 variant antibodies or fragments thereof.
3.WO/2020/099922ANTIBODIES AGAINST DISEASE CAUSING AGENTS OF CANINES AND FELINES AND USES THEREOF
WO 22.05.2020
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
Appl.No PCT/IB2019/001196 Applicant NOVOBIND LIVESTOCK THERAPEUTICS, INC. Inventor ABNOUSI, Hamlet
Described herein are methods and antibodies useful for reducing, eliminating, or preventing infection with a viral population in an animal. Also described herein are antigens useful for targeting by heavy chain antibodies and VHH fragments for reducing a viral population in an animal.
4.WO/2020/093159BROADLY-NEUTRALIZING ANTIBODY AND NEURAMINIDASE INHIBITOR COMBINATIONS TO PREVENT OR TREAT INFLUENZA VIRUS INFECTIONS
WO 14.05.2020
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/CA2019/051582 Applicant MCMASTER UNIVERSITY Inventor MILLER, Matthew
The present application relates to methods and compositions for preventing or treating influenza virus infections. In particular, the present application relates to the use of one or more broadly-neutralizing antibodies (bNAbs) in combination with one or more neuraminidase inhibitors such as oseltamivir for the prevention or treatment of influenza infections. In particular, the one or more broadly-neutralizing antibodies bind to the stalk domain of hemagglutinin (HA).
5.WO/2020/089742ANTI-RABIES MONOCLONAL ANTIBODIES AND COCKTAIL THEREOF
WO 07.05.2020
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
Appl.No PCT/IB2019/059118 Applicant CADILA HEALTHCARE LIMITED Inventor MENDIRATTA, Sanjeev Kumar
The disclosure provides a murine monoclonal antibody capable of binding and neutralizing rabies or rabies related viruses. It also provides a cocktail of at least two monoclonal antibodies with said properties. The cocktail can neutralize the virus that is derived from species such as bats, dogs, cows, mongooses, skunks, and wolves, and thus can be useful in treating a patient that has potentially been infected. Further, the disclosure provides a combination of muring monoclonal antibody or cocktail of at least two monoclonal antibodies and anti-rabies vaccine for use in post-exposure prophylaxis (PEP) with rabies or rabies-related viruses.
6.20200140528Broadly Neutralizing Anti-HIV Antibodies and Epitope Therefor
US 07.05.2020
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 16578833 Applicant The Rockefeller University Inventor Michel Nussenzweig

The present invention relates to broadly neutralizing anti-HIV-1 antibodies and isolated antigens. Also disclosed are related methods and compositions.

7.20200129618ANTIBODY THERAPIES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV)
US 30.04.2020
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
Appl.No 16535921 Applicant Beth Israel Deaconess Medical Center, Inc. Inventor Dan H. BAROUCH

This invention relates to antibody therapies for human immunodeficiency virus (HIV). In particular, the invention provides methods of curing subjects infected with HIV and blocking HIV infections in subjects at risk of HIV transmission using a N332 glycan-dependent antibody (e.g., PGT121).

8.WO/2020/082045MULTISPECFIC ANTI-HIV ANTIBODIES
WO 23.04.2020
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
Appl.No PCT/US2019/057089 Applicant UNIVERSITY OF MARYLAND, COLLEGE PARK Inventor LI, Yuxing
The present invention provides a multispecific anti-HIV antibody that binds to multiple epitopes on HIV envelope protein, wherein the antibody comprises: i. an amino acid sequence that binds to a V1/V2 apex glycan epitope; ii. an amino acid sequence that binds to a V3-base glycan region epitope; iii. an amino acid sequence that binds to a CD4 binding site (CD4bs) epitope; iv. an amino acid sequence that binds to a gp120/gp41 interface epitope; and v. an amino acid sequence that binds to a membrane proximal external region (MPER) epitope.
9.111012907一种抗山羊副流感的饲料添加剂制备方法及应用
CN 17.04.2020
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
Appl.No 201911418333.5 Applicant 江苏省农业科学院 Inventor 常晨
本发明所述一种抗山羊副流感的饲料添加剂制备方法及应用,其中组合物包括以下重量份数的组分:抗山羊副流感卵黄抗体65‑69份、抗山羊副流感转移因子0.5‑1.8份;饲料添加剂包括以下重量份数的组分:抗山羊副流感卵黄抗体65‑69份、抗山羊副流感转移因子0.5‑1.8份、防腐剂0.01‑0.015份、灭活剂0.4‑0.5份、维生素C0.5‑1份、维生素B0.6‑1份、聚乙烯吡咯烷酮2‑3份、甘氨酸0.25‑0.8份。本发明将抗山羊副流感卵黄抗体与抗山羊副流感转移因子复配,可以显著提高防治山羊副流感的效果,具有针对性强,常温下保存时间长,抗体效价高,生物活性良好的优点。
10.111018971柯萨奇病毒A6型实心病毒的单克隆抗体及其应用
CN 17.04.2020
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 201911380623.5 Applicant 北京科兴生物制品有限公司 Inventor 武瑞霞
本发明公开了一种能与柯萨奇病毒A6型实心病毒反应的单克隆抗体,并公开了含有该单抗的试剂盒及其应用。本发明采用纯化的CA6病毒液免疫小鼠制备单克隆抗体。本发明还公开了所述单克隆抗体在检测CA6病毒或诊断手足口病中的应用。所述单克隆抗体对于快速检测试剂盒的制备和疫苗的开发研究,具有广泛的应用。